Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
Status:
Terminated
Trial end date:
2017-03-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral
solution when administered to healthy subjects three times a day (TID) for 7 days.
Phase:
Phase 1
Details
Lead Sponsor:
Emergent BioSolutions
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)